$NBIO Macro Lines Up with Micro: Nov 30, 2022
Post# of 26594
![Avatar](/images/ProfileImages/734810790_1098_wst.png)
Nov 30, 2022 (WallStreetPR via Comtex) -- With the Biotechnology space rotating toward a more acquisition friendly dynamic, investors may benefit from a studied focus on likely takeout candidates - particularly early-stage pipelines with recent identifiable traction targeting large end markets.
One such example is Nascent Biotech Inc. (OTCMKTS:NBIO), an emerging player in the $4 billion oncology drug development space.
NBIO is certainly early-stage: its flagship drug is just heading toward Phase 2 clinical research, right in the sweet spot for dealmaking as a potential acquisition target as deals pick up pace this cycle. https://www.marketwatch.com/press-release/fis...re_twitter
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)